Dianthus Therapeutics (NASDAQ:DNTH) vs. Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison

Oramed Pharmaceuticals (NASDAQ:ORMP) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Oramed Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Oramed Pharmaceuticals and Dianthus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Dianthus Therapeutics	0	0	8	2	3.20

Dianthus Therapeutics has a consensus price target of $44.71, indicating a potential upside of 65.67%. Given Dianthus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Oramed Pharmaceuticals.

Profitability

This table compares Oramed Pharmaceuticals and Dianthus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	2.70%	2.10%
Dianthus Therapeutics	-1,376.42%	-21.03%	-20.18%

Valuation & Earnings

This table compares Oramed Pharmaceuticals and Dianthus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$1.34 million	72.77	$5.53 million	$0.26	9.23
Dianthus Therapeutics	$4.12 million	196.63	-$43.56 million	($5.83)	-4.73

Oramed Pharmaceuticals has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Dianthus Therapeutics beats Oramed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.